Hal V. Barron

Throughout the industry, I found that the early days of massive startups touting grand plans had been replaced by more careful talk, and companies now primarily highlight the practical near-term benefits of their work.

The CEO of Altos Labs, Hal Barron, told me that Altos wanted medicine to move from a disease care model to a true health care model.

And Jerry McLaughlin, the CEO of Life Biosciences, which licensed Sinclair's ER100 treatment, emphasized the focus of their work was really on the quality of life, not its length.

But Sinclair remained unafraid to make the claims others danced around.